A Stock Analysis — Agilent Technologies
Sector: Healthcare
AI Verdict
Agilent trades at 21.5x next year’s earnings for nearly 40% expected EPS growth, which is cheap for the growth you’re getting if its recurring consumables moat keeps delivering, but the overbought RSI means short-term downside risk is real.
Competitive Moat
Agilent dominates in laboratory instruments and diagnostics with a broad installed base and proprietary consumables that create recurring revenue from customers who are locked into its workflow. Its scale and deep integration with pharma and biotech R&D make it hard for smaller rivals to displace, especially as labs standardize on Agilent’s platforms.
Summary
Agilent’s stock is running hot as analysts expect nearly 40% earnings growth next year, pushing its RSI into overbought territory.
Where It Stands
Shares are up 25.59% over the past year, trade at 21.5x forward earnings (vs. the healthcare median of 22x), and the RSI of 79.3 signals the stock is overbought.
Key Metrics
- RSI: 79.3 — Overbought
- Trailing P/E: 30.0x
- Forward P/E: 21.5x
- PEG Ratio: 0.75
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $42.2B
- Dividend Yield: 0.01%
- 1-Year Return: 25.59%
- 52-Week High: $160.27
- 52-Week Low: $108.35
Analyst Consensus
22 Buy · 7 Hold · 0 Sell (29 analysts)
Bull Case
With forward EPS growth projected at 39.7% and a forward P/E of 21.5x, you’re paying a below-median price for much faster-than-average expected earnings expansion.
Bear Case
The RSI at 79.3 means the stock is overbought, so even a modest pullback to neutral RSI could erase a chunk of the recent 25.59% gain.
Catalyst to Watch
Watch for upcoming earnings — if Agilent delivers on the 39.7% EPS growth forecast, the current valuation holds up; any miss could trigger a sharp correction.